[{"id":"ffb94954-f1c1-4247-b33c-267b8f6f3014","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231851","created_at":"2021-01-18T20:35:11.661Z","updated_at":"2024-07-02T16:35:20.841Z","phase":"Phase 2","brief_title":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","source_id_and_acronym":"NCT04231851","lead_sponsor":"University of California, Irvine","biomarkers":" NPM1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • Daurismo (glasdegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/19/2020","start_date":" 02/19/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-02-05"},{"id":"629a9570-5526-4e21-a561-e5d4879b487d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03390296","created_at":"2021-01-18T16:43:54.834Z","updated_at":"2024-07-02T16:35:38.199Z","phase":"Phase 1/2","brief_title":"OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03390296","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Bavencio (avelumab) • azacitidine • Mylotarg (gemtuzumab ozogamicin) • Daurismo (glasdegib) • ivuxolimab (PF-04518600)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 02/04/2022","primary_completion_date":" 02/04/2022","study_txt":" Completion: 02/04/2022","study_completion_date":" 02/04/2022","last_update_posted":"2023-09-04"},{"id":"f514e125-fc12-410e-8afb-782e274842a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04655391","created_at":"2021-01-19T20:41:28.630Z","updated_at":"2024-07-02T16:36:09.137Z","phase":"Phase 1b","brief_title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04655391","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • ABL1 • BCR • IDH1 • AXL","pipe":" | ","alterations":" IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836","tags":["FLT3 • ABL1 • BCR • IDH1 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • Bosulif (bosutinib) • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/25/2022","start_date":" 06/25/2022","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-06-09"},{"id":"96842ea0-1da9-4149-ba34-ced2a2b292bb","acronym":"BRIGHT AML","url":"https://clinicaltrials.gov/study/NCT01546038","created_at":"2024-01-07T00:16:58.018Z","updated_at":"2024-07-02T16:36:49.330Z","phase":"Phase 1b/2","brief_title":"A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT01546038 - BRIGHT AML","lead_sponsor":"Pfizer","biomarkers":" RUNX1","pipe":"","alterations":" ","tags":["RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • daunorubicin • Daurismo (glasdegib)"],"overall_status":"Completed","enrollment":" Enrollment 255","initiation":"Initiation: 06/27/2012","start_date":" 06/27/2012","primary_txt":" Primary completion: 01/03/2017","primary_completion_date":" 01/03/2017","study_txt":" Completion: 03/04/2019","study_completion_date":" 03/04/2019","last_update_posted":"2020-03-03"}]